


We claim:

1. A compound of Formula (Ib) or a pharmaceutically acceptable salt thereof,




wherein:

one R^A is halo and one R^A is aryl or heteroaryl, wherein each of aryl, or heteroaryl is independently substituted with 0-5 occurrences of R^a ;


each R^a is independently selected from halo, cyano, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkoxy, $-N(R'')(R'')$, $-C(O)-N(R'')(R'')$, $-N(R'')-C(O)R'$, and $-(C_1-C_6 \text{ alkylene})-N(R'')-C(O)R'$;

each R' and R'' is independently selected from hydrogen, C_1 - C_6 alkyl and C_1 - C_6 hydroxyalkyl.

2. A compound of Formula (Ic) or (Ic-1):



(Ic),



(Ic-1), or a

pharmaceutically acceptable salt thereof, wherein:

X is N or $C(R^9)$;

R^{A1} is fluoro or $-CN$;

R^{A2} is fluoro or hydrogen;

R^{B1} is hydrogen or fluoro;

R^9 is selected from hydrogen, halo, -CN, -C₁-C₄ alkyl, -C(O)N(R¹¹)(R¹¹), and -S(O)₂N(R¹¹)(R¹¹), wherein any alkyl portion of R^9 is optionally substituted with one or more substituents selected from -OH and -F;



R^{10} is selected from hydrogen, halo, -O-(C₁-C₄ alkyl) optionally substituted with one or more halo, and -C(O)N(R¹¹)(R¹¹); and






each R^{11} is independently selected from hydrogen, and C₁-C₄ alkyl optionally substituted with one or more substituents selected from -OH and cyclopropyl.






3. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R^9 is selected from hydrogen, fluoro, chloro, -CN, -C(O)NH₂, -C(O)NHCH₃, -C(O)N(CH₃)₂, -C(O)NHCH₂CH₂OH, -C(OH)(CH₃)₂, -S(O)₂NH₂, and N-(cyclopropylmethyl)carbamyl.






4. The compound of claim 2 or 3, or a pharmaceutically acceptable salt thereof, wherein R^{10} is selected from hydrogen, fluoro, chloro, -OCH₃, -OCF₃ and -C(O)NH₂.






5. A compound selected from any one of the compounds in the table below and a pharmaceutically acceptable salt thereof:

Compound Number	Structure
1	
2	


3	
4	
5	
6	
7	

8	
9	
10	
11	
12	

13	
14	
15	
16	
17	


18	
19	
20	
21	
22	

6. A compound selected from




and a pharmaceutically acceptable salt thereof.

7. A compound selected from




and a pharmaceutically acceptable salt thereof.

8. A compound selected from




and a pharmaceutically acceptable salt thereof.

9. A compound selected from



and a pharmaceutically acceptable salt thereof.

10. A compound selected from



and a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound of any one of claims 1-10 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

12. Use of a therapeutically effective amount of a compound of any one of claims 1-10 or a pharmaceutically acceptable salt or composition thereof in the manufacture of a medicament, for treating a condition mediated by aberrant neurotrophic tyrosine receptor kinase (NTRK) activity in a subject,

wherein the condition mediated by aberrant neurotrophic tyrosine receptor kinase (NTRK) activity is selected from non-small cell lung cancer, breast cancer, melanoma, low and high grade glioma, glioblastoma, pediatric astrocytoma, colorectal cancer, thyroid cancer, pancreatic cancer, biliary cancer, head and neck cancer, primary CNS tumors, cholangiocarcinoma, acute myelogenous leukemia, breast cancer, salivary gland cancer, sarcoma, and spitzoid neoplasms.

13. Use of a therapeutically effective amount of a compound of any one of claims 1-10 or a pharmaceutically acceptable salt or composition thereof in the manufacture of a medicament for treating a cancer in a subject who has developed resistance to a cancer treatment, wherein the cancer is non-small cell lung cancer, breast cancer, melanoma, low and high grade glioma, glioblastoma, pediatric astrocytoma, colorectal cancer, thyroid cancer, pancreatic cancer, biliary cancer, head and neck cancer, primary CNS tumors, cholangiocarcinoma, acute myelogenous leukemia, breast cancer, salivary gland cancer, sarcoma, or spitzoid neoplasms.

14. A compound of any one of claims 1-10 or a pharmaceutically acceptable salt or composition thereof for use in inhibiting neurotrophic tyrosine receptor kinase (NTRK) activity in a subject,

wherein the subject has non-small cell lung cancer, breast cancer, melanoma, low and high grade glioma, glioblastoma, pediatric astrocytoma, colorectal cancer, thyroid cancer, pancreatic cancer, biliary cancer, head and neck cancer, primary CNS tumors, cholangiocarcinoma, acute myelogenous leukemia, breast cancer, salivary gland cancer, sarcoma, or spitzoid neoplasms.

15. A compound of any one of claims 1-10 or a pharmaceutically acceptable salt or composition thereof for use in treating a subject suffering from a condition mediated by aberrant neurotrophic tyrosine receptor kinase (NTRK) activity,

wherein the condition mediated by aberrant neurotrophic tyrosine receptor kinase (NTRK) activity is selected from non-small cell lung cancer, breast cancer, melanoma, low and high grade glioma, glioblastoma, pediatric astrocytoma, colorectal cancer, thyroid cancer, pancreatic cancer, biliary cancer, head and neck cancer, primary CNS tumors, cholangiocarcinoma, acute myelogenous leukemia, breast cancer, salivary gland cancer, sarcoma, and spitzoid neoplasms.

16. A compound of any one of claims 1-10 or a pharmaceutically acceptable salt or composition thereof for use in treating a subject who has developed resistance to a cancer treatment.

17. Use of a compound of any one of claims 1-10 or a pharmaceutically acceptable salt or composition thereof in the manufacture of a medicament for treating a cancer selected from non-

small cell lung cancer, breast cancer, melanoma, low and high grade glioma, glioblastoma, pediatric astrocytoma, colorectal cancer, thyroid cancer, pancreatic cancer, biliary cancer, head and neck cancer, primary CNS tumors, cholangiocarcinoma, acute myelogenous leukemia, breast cancer, salivary gland cancer, sarcoma, and spitzoid neoplasms in a subject by inhibiting neurotrophic tyrosine receptor kinase (NTRK) activity.